GLG News by Hematologists who Treat Myelodysplastic Syndromes

Lilly will likely get front line approval for Alimta in non small cell lung cancer Most patients with advanced disease never see a response to therapy

"ASA404 is a Tumor-Vascular Disrupting Agent (Tumor-VDA) that selectively causes the collapse of existing tumor blood supply leading to extensive tumor cell death." It is being combined with Taxol and carboplatin in a randomized phase III study.

Alimta will be used first line with Cis Platin as a primary therapy for non squamous non small cell lung cancer (NSCLCA)

2 Texas U.S. Reps think that physcian owned hospitals are OK?

Co payments which had been $5/10/20 in the past are now a %age of the cost. When the cost may be upwards of $50-100K and you have a 20% co pay you can see the costs that are transfered back to the insured.

Has Avastin "hit the wall" as far as increased sales are concerned? Growth in the breast cancer market has not been as exuberant as expected.

Japan's biggest (by revenue) drug manufacturer has placed a bid For Millennium and it's primary product Velcade.

"Senicapoc, a novel Gardos channel inhibitor, limits solute and water loss, thereby preserving sickle red blood cell (RBC) hydration." This appears to decrease hemolysis and increase hemoglobin levels.

This study, as well as a companion paper in the same JCO (Spirit I & II) http://jco.ascopubs.org/cgi/content/full/26/11/1886 Show that the subset of patients with markedly increase in lipids, survived > 12 mo!!

Antigenics Inc. (NASDAQ: AGEN) had to go to Russia to perform this clinical trial???